Dextranomer/Hyaluronic Acid for Pediatric Vesicoureteral Reflux: Systematic Review abstract OBJECTIVE: Published success rates of dextranomer/hyaluronic acid (Dx/HA) injection for pediatric vesicoureteral reflux (VUR) vary widely. Our objective of this study was to assess whether underlying patient or study factors could explain the heterogeneity in reported Dx/HA success rates.
In 2001, the Food and Drug Administration approved the use of dextranomer/ hyaluronic acid (Dx/HA) copolymer (Deflux [Q-Med, Uppsala, Sweden]), for endoscopic injection in children with primary grades 2 to 4 vesicoureteral reflux (VUR). As a result in large part of the minimally invasive nature of Dx/HA treatment, injection use has rapidly increased. 1, 2 The reportedly low morbidity of Dx/HA injection has prompted some investigators to recommend it as a first-line alternative to traditional therapeutic standards of antibiotic prophylaxis or ureteroneocystostomy, despite an absence of trials comparing these modalities. 3 Full characterization of the effectiveness of Dx/HA injection has been difficult, given that reported success rates range from 50% to 100%. 4, 5 Direct comparisons of published series have also been difficult, mainly because of patient heterogeneity, differences in injection technique, and varying definitions of treatment "success." Despite these complicating factors, multiple groups have proposed prognostic factors for Dx/HA injection outcome to aid in the identification of the ideal Dx/HA candidate. 4, 6 Chief among these factors has been preoperative VUR grade and the presence of complicating clinical features such as anatomic bladder and ureteral abnormalities. Other reported factors include surgeon (or surgeon experience), injected Dx/HA volume, and injection technique. 6, 7 Some groups that have reported high success rates have disclosed industry conflicts of interest (COIs), which have been shown to have a negative impact on the results and quality of published research. 8, 9 To our knowledge, the importance of COI has not yet been addressed in the setting of pediatric urologic research. Given the vulnerability of pediatric populations to clinical research and the presence of policies aimed at increasing industry participation in pediatric research, consideration of the presence of COIs in pediatric urology seems warranted. 10, 11 The goal of this systematic review was to evaluate the accumulated literature on the surgical treatment of pediatric VUR by using Dx/HA and to determine the extent to which reported success rates are influenced by preoperative VUR grade, COIs, or other underlying patient-or study-level factors.
METHODS

Search Strategy
We searched the Cochrane Controlled Trials Register and Medline, Embase, and Scopus electronic databases for studies published between January 1990 and December 2008 in any language. A deliberately wide date range was chosen to capture all reports of Dx/HA use. The exploded search terms used were "injection," "hyaluronic acid," "dextranomer," "dextranomer hyaluronic acid," "Deflux," and "Zuidex." These were then restricted to articles that were retrieved under a second search for the exploded search terms "vesicoureteral reflux" and "reflux." Reference lists of included studies were screened for missed studies. We also manually searched for unpublished abstracts that were presented at the following scientific meetings: the American Urological Association, the American Academy of Pediatrics Section on Urology, the European Society of Pediatric Urology, and the Canadian Urological Association.
Selection Criteria
All retrieved articles that described Dx/HA injections for VUR in children (aged 0 -18 years) were reviewed. No article was excluded on the basis of study design, method of analysis, definition of success, language of publication, or perceived quality. Because of the presence of publications with overlapping cohorts (typically case series and their updates), we required that at least 75% of study patients not be previously reported. We additionally required that the number of patients treated and the fraction for which the treatment was successful be reported and that the mean age of the study cohort meet our age requirements (Ͻ18 years). For studies that reported use of multiple injectable agents, we required that the Dx/HA-specific success rates be reported or easily determinable. In cases of ambiguity or when study reporting made evaluation difficult, we attempted to err on the side of inclusiveness.
Data Abstraction
Two reviewers (Drs Routh and Inman) independently reviewed all study abstracts in duplicate and resolved disagreements by consensus. The full text of articles that seemed to meet selection criteria were reviewed, and study data were abstracted in duplicate. Articles that were published in languages other than English were translated by study authors who were fluent in that language and/or by institutional translation staff. Abstracted data included patient age, volume of Dx/HA injected, preoperative VUR grade, study design, country of origin, COI disclosure, reported definition of a successful injection, and clinical markers of higher risk patients (posterior urethral valves, ureteral diverticula or duplication, previous bladder surgery, neurogenic bladder, ureterocele, or repeat injections). COI was identified by disclosure publication as previously described. 12 
Missing Data and Author Contact
In cases of missing or unreported data, we attempted to contact study authors by both e-mail and written communication. In cases in which authors were unable to provide the missing information, we excluded the study only from analyses that required the missing data. We also unsuccessfully attempted to contact the manufacturer of Dx/HA by e-mail, telephone, and written communication to obtain information regarding support of study authors and to discover any unpublished data regarding Dx/HA use for VUR.
Outcome Assessment
The outcome of interest was the postoperative success rate after a single Dx/HA injection, expressed as the proportion (95% confidence interval [CI]) of cases treated. We defined a failed Dx/HA injection as the persistence of VUR of any grade on postoperative imaging. For studies that defined "success" to include grade 1 VUR, we included these data but conducted sensitivity analyses to determine how such studies affected the pooled success estimates.
Only per-ureter success rates were analyzed; when these could not be determined, we extrapolated from perpatient cure rates. For studies that combined multiple Dx/HA injections or multiple injected substances, only the Dx/HA-specific rates after the first injection were analyzed. Simple proportions were used for effect estimates, in accordance with previously published methods. 13 
Statistical Methods
For univariate pooling, standard fixedand random-effects models were constructed with inverse variance weighting. [13] [14] [15] Meta-regression was performed by using multilevel regression models that evaluated study-level parameters (COI, "success" definition, country of origin), and patient-level parameters (preoperative VUR grade, age, injected volume). We used a series of nested models to determine which characteristics affected the likelihood of injection success; VUR grade was used as a covariate in each model, sequentially combined with each of the aforementioned parameters. Anatomic and functional abnormalities (eg, posterior urethral valves, previous bladder surgery) were infrequently reported, which rendered their inclusion in the meta-regression infeasible. As such, only pooled mean (95% CI) success rates were calculated. Study heterogeneity was assessed using Cochran's Q and HigginsThompson I 2 statistics. 14, 16 Influence analyses were performed by sequentially removing each study and reanalyzing pooled success rates. All statistical analyses were performed by using R 2.9.0 with packages lme4, meta, and arm installed.
RESULTS
After screening the abstracts of an initial 1157 reports, we reviewed the full text of 89 studies (Fig 1) . Of these, 47 studies met our inclusion criteria and were abstracted (Table 1) . Of 7303 ureters injected with Dx/HA, 5633 (77% [95% CI: 76%-78%) were successfully treated (Fig 2) . Study results were markedly heterogeneous, with 87% of the total variability in pooled outcomes related to between-study variability (I 2 ϭ 87% [95% CI: 84%-90%).
Meta-regression revealed that preoperative VUR grade was the single most important factor affecting the Dx/HA injection success rate (Table 2) . Children with grade 1 VUR had an 81% probability (95% CI: 70%-90%) of successful injection, whereas those with grade 5 VUR had only a 62% probability (95% CI: 54%-72%; P Ͻ .0001). Thirty-one studies of 5149 injected ureters reported sufficient detail that per-grade results could be analyzed. Dx/HA injection success rates decreased with increasing preoperative VUR grade (Fig 3) . It is interesting that when plotted by VUR grade the success rate of Dx/HA injection was not linear but rather sigmoidal (Fig 4) , suggesting that the risk for Dx/HA failure was only slightly higher for grade 2 than for grade 1. Similarly, the risk for injection failure for grade 5 was not substantially higher than that for grade 4.
After adjustment for VUR grade, COI disclosure was not independently associated with an increased success rate (74% without COI vs 78% with COI; P ϭ .2). In total, 9 studies of 1190 ureters that underwent Dx/HA injection disclosed a relevant COI, whereas 34 studies of 5926 ureters did not report a COI (Fig 5) . The remaining 4 studies of 
FIGURE 1
Flow diagram for literature search and study review.
187 ureters did not include enough information to determine COI status, chiefly because the publication was in abstract format only; however, Monte Carlo simulations that were based on this meta-regression model predicted Dx/HA success in studies with reported COIs of 89%, 88%, 79%, 63%, and 75% for grades 1 through 5, respectively. Predicted Dx/HA success rates were somewhat lower for studies that did not report COI, at 85%, 84%, 71%, 53%, and 67%, respectively. This suggests that COIs may result in the reporting of better success rates for higher risk (ie, higher grade) VUR, even despite its nonsignificant effect after adjustment for VUR grade.
Similarly, after adjustment for grade in other exploratory meta-regression models, increasing patient age (P ϭ .07), the definition of "success" (P ϭ .3), and increasing volume of Dx/HA in- Cumulative meta-analysis did not reveal a temporal bias to success rates (ie, the year a study was published was not associated with its success rate). Influence analysis did not identify any 1 study that was statistically overly influential; however, the studies of Alkan et al, 17 Biocic et al, 18 Capozza et al, 19 and Puri et al 20 tended to increase the pooled success rate, whereas the studies of Dahl et al, 21 Altug et al, 22 and Dave et al 4 tended to lower the overall pooled success rate. In addition, the studies of Dahl et al 21 and Puri et al 20 introduced the highest amount of between-study variance into the pooled meta-analysis, suggesting that the success rates of these studies were lower and higher, respectively, than those of other studies.
DISCUSSION
The accumulated Dx/HA literature encompasses a wide range of study designs and methods. Few of the studies that we encountered were highquality, prospective studies, and fewer still were well-reported randomized trials. By and large, most published studies were retrospective case series. Given the commonness of pediatric VUR and the rapidly expanding use of Dx/HA in its treatment, this lack of high-level data is disturbing. Clearly, there is an urgent need for randomized trials that are designed to address the utility of Dx/HA injection in comparison with other forms of therapy, including ureteroneocystostomy, antibiotic chemoprophylaxis, and, for
FIGURE 2
Forest plot of all studies. some patients, a lack of treatment altogether. Alternatively-particularly given the inherent difficulty of randomly assigning patients to surgical treatment-this area would seem to be particularly well-suited as a target for comparative effectiveness research.
Despite this lack of substantive data, Dx/HA use has dramatically increased in recent years, 1 with some authors even recommending Dx/HA injection as the optimal first-line VUR treatment. 3 Although this increased use is generally attributed to the minimally invasive nature and perceived technical simplicity of the injection, industry marketing and generous research support may also play a role. Previous research demonstrated that industry sponsorship can affect both the results and the interpretation of clinical research. 8, 9 Such studies have prompted much debate in the medical community as to the appropriate role of industry in research, as well as the nature of research-associated financial disclosures. 23 Given the tremendous outcome variability with Dx/HA, the dearth of high-quality studies, and the frequency of industry support, we believed that a systematic review of the literature could be useful to determine better which factors influence reported injection success rates.
We hypothesized that the reported success rates of Dx/HA injection for pediatric VUR would differ depending on the presence of COI, on the preoperative VUR grade, and on other clinical factors. Our findings confirm the impact of preoperative VUR grade on injection success rates and suggest that the presence of clinical factors (eg, posterior urethral valves or ureteral duplication) negatively influence success rates. Furthermore, these data seem to suggest a trend toward increased success rates in industrysupported studies, although it should be noted that this trend was not statistically significant after adjustment for VUR grade. This suggests the possibility that COIs may be a source of selection bias in Dx/HA studies; alternatively, industry sponsors may simply be particularly adept at selecting skilled or successprone surgeons to support.
A particular area of concern is the typically short follow-up for Dx/HA studies; rarely do studies report radiographic follow-up beyond 3 months after injection. It is interesting that studies that did follow their patients for longer periods universally reported a significant loss of effectiveness over time. A recent study by Lee et al 24 reported a success rate of only 46% at 1 year; studies by Lä ckgren et al 25 and Oswald et al 26 also noted a significant failure rate with extended follow-up. Although the number of pa-
FIGURE 3
Forest plot of studies grouped by preoperative VUR grade.
FIGURE 4
Bubble plot of study success rates by preoperative VUR grade.
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PEDIATRICS Volume 125, Number 5, May 2010tients who will experience a late failure has varied with study method, it is clear that a substantial proportion of "cured" patients will fail if followed for a sufficiently long time. Given that the average child who underwent injection was only 5 years old and given that VUR has the potential for long-term morbidity, 3 months of follow-up seems to be woefully inadequate. More important, this suggests that our pooled success rate of 77% may be a significant overestimation. This study should be interpreted in light of its limitations. As with any systematic review, our analyses were limited by the available data from the included studies. Published studies of Dx/HA use for the treatment of pediatric VUR are predominantly lower quality studies such as case series, and prospective cohort or randomized, controlled studies on this subject are rare. Rarer yet are studies that report their findings in a manner such that their data are easily amenable to systematic review. We found it quite difficult, in many cases, to extract data for inclusion in our study. This led us to attempt to contact the authors of included articles asking them to confirm (and in most cases supplement) the data from their articles. Unfortunately, most authors did not respond to our requests, and we were thus forced to rely on a potentially imperfect data set.
Second, it is important to note that we conducted our risk analyses at the study level instead of at the patient level. This is a form of ecologic bias, whereby the aggregate results across studies are different from the raw results within studies. This possible bias is perhaps best demonstrated in Fig 4; notably, the results for grade 5 VUR are higher than might be expected if grade had a linear effect on treatment success. This is further evidenced by the fact that individual studies tended to show a strong trend in efficacy on the basis of VUR grade. 6, 7, 28 Similarly, it should be noted that our analysis of author factors such as COIs are highly dependent on the veracity of author disclosures. Although we have no reason to suspect that groups were not wholly forthright in their disclosures, it is important to note that the omission or false report of COIs in even a small number of groups could have significantly affected our findings.
Last, it is worthwhile to note that although this systematic review was not intended to compare different injectable agents, our unadjusted results correspond well with previous meta-analyses of endoscopic injection by using a variety of biomaterials. 27 Although Dx/HA offers significant advantages as an injectable agent, notably that it is Food and Drug Administration-approved and unlikely to migrate after injection, Dx/HA results seem to be quite comparable to results seen with other agents.
CONCLUSIONS
The overall per-ureter Dx/HA success rate was 77% 3 months after injection, although success rates varied widely among studies. Increasing VUR grade negatively affects injection success rates, whereas COI, patient age, injected Dx/HA volume, and success definitions were not significantly associated with treatment outcome after adjustment for VUR grade. There is a significant need to improve the reporting and method of Dx/HA studies, particularly to design and execute comparative studies of Dx/HA and other treatments for VUR.
